Overview

We were formed in 2014 by neuroscience researchers at the Swiss Federal Institute of Technology (EPFL). We are headquartered in Eindhoven, the Netherlands, with an office in Lausanne, Switzerland and a growing US team based in Boston, Massachusetts.

Meet the team

  • Dave Marver, CEO

    Dave Marver

    Chief Executive Officer

    Dave Marver joined ONWARD in July 2020. An accomplished chief executive and director with more than 25 years of international experience in public, private, and emerging companies, he combines expertise in medical and consumer technology, wearables, and health monitoring. Previously, Dave spent almost 15 years with Medtronic in a variety of leadership positions in the US and Europe, including Vice President roles in Sales, Marketing, Strategy, and Business Development. He then joined NASDAQ-listed Cardiac Science Corporation as CEO, before co-founding two start-ups. He holds a BA in Psychology from Duke University and an MBA from University of California Los Angeles.
  • Erika

    Erika Ross Ellison, PhD

    VP of Clinical, Regulatory, & Quality no just Clinical & Regulatory

    Erika Ross Ellison brings extensive expertise in neuromodulation, with experience in clinical trial design and execution for class II and III neurostimulation technologies.  She joins ONWARD from Abbott Neuromodulation, where she was Director, Global Clinical & Applied Research. Previously, as Neuroscience Director at Cala Health, she managed the scientific research program that led to de novo clearance and launch of the company’s neurostimulation technology. She also brings outstanding relationships with researchers and clinicians, forged during her years as Deputy Director, Medical Device Innovation Accelerator, Department of Surgery, and Assistant Professor, Department of Neurologic Surgery at Mayo Clinic. Erika holds a BSc in Biology and Business and an MSc in Molecular Biology from the University of Denver and a PhD in Neuroscience from Mayo Clinic.
  • Julien Camisani

    Julien Camisani

    Vice President, Engineering

    Julien Camisani brings more than twenty years of experience, fifteen of which are in the life sciences industry, where he has been instrumental in inventing, developing, marketing, and sustaining advanced laboratory, medical and bio-manufacturing technologies. Prior to joining ONWARD® Medical, Julien led diverse and global teams, and managed large-scale projects with proven leadership across research and development, manufacturing, intellectual property and product management for companies like Cytiva, GE Healthcare and Biosafe. He holds dual master’s degrees in Embedded Systems from the University of Lugano, collaborating with ETH Zurich and Politecnico di Milano, complemented by an MBA from the University of Cumbria and a professional certificate in Technology Road mapping and Strategic Innovation from MIT.
  • Bob Odell

    Bob Odell

    Vice President, Operations

    Bob Odell brings to ONWARD decades of leadership experience in the medical device industry. Prior to joining ONWARD, Bob was President and Chief Operating Officer of Cardiac Insight, Inc., a successful startup that introduced disruptive technology to the global marketplace. Prior to Cardiac Insight, he served as COO for Cardiac Science, a publicly traded manufacturer of Class II and Class III devices. Bob has held executive assignments in Operations, Engineering, Marketing, Business Development. Information Technology and General Management with such notables as GE Healthcare, Siemens Medical Solutions, Philips Medical Systems, Medtronic, and Analogic. The foundation for his career is a degree in electrical and computer engineering from Syracuse University.

  • Amori Fraser

    Amori Fraser

    Finance Director

    Amori Fraser serves as the Finance Director at ONWARD Medical, leveraging over 18 years of experience in both finance and auditing. Prior to her current role, she worked as a Senior Manager at EY, specializing in financial reporting, regulatory compliance, financial analysis and internal controls serving multi-national listed groups. Amori's experience in auditing and finance enables her to drive efficient financial operations and support the company’s growth initiatives. Amori holds a BComHons degree in Accounting Sciences from the University of Pretoria and is a qualified Chartered Accountant (CA) with the South African Institute of Chartered Accountants (SAICA).

  • Alexandre Casteau

    Alexandre Casteau

    Head of Strategy & Corporate Development

    Alexandre Casteau brings extensive healthcare corporate strategy expertise. A former management consultant with McKinsey & Company, Alexandre spent several years advising global life science businesses on growth strategy and large-scale transformations. He also launched and led the McKinsey Switzerland startup/scaleup service line, providing a differentiated strategy consulting offering to help early-stage, fast-growing companies scale. Earlier in his career, Alexandre held a variety of roles at Endeavor, Rocket Internet SE and Société Générale Corporate & Investment Banking. He holds an MBA from INSEAD and an MSc. from MIT.
  • Julie Crom

    Julie Crom

    Director, People & Culture

    Julie Crom has more than 10 years of experience in Human Resources in the medical devices industry. Prior to joining ONWARD Medical, Julie served as Healthcare & Life Sciences Practice Lead at Michael Page, a leading recruitment company in Europe. In her role, she supported middle-to-large medical device companies in recruitment and organizational strategy. Julie holds an MSc in International Business Management from INSEEC business school.
  • Lorenzo Fanti

    Lorenzo Fanti

    Vice President, Legal

    Lorenzo Fanti is a dual-qualified US and English attorney with nearly 15 years of experience specializing in pharmaceuticals and medtech. Prior to joining ONWARD Medical, Lorenzo served as worldwide Legal Head, Ophthalmology ad interim at Novartis Pharmaceuticals, and, prior to that, he was Country Legal Head for Chile ad interim for the Novartis group of companies. He has held various roles with increasing responsibility at Novartis, including in the Neuroscience franchise, where he contributed to the launch of innovative migraine treatments. Early in his career, he was a Trademark Paralegal with Sandoz, and he trained with Allen & Overy LLP in London. He holds an LL.B. from the University of Wales.

Recent News

31 Oct 24
ONWARD ARC-EX® System Named One of TIME's Best Inventions of 2024

EINDHOVEN, the Netherlands, Oct. 31, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces its investigational ARC-EX System has been named one of TIME's Best Inventions of 2024.

28 Oct 24
ONWARD® Medical Publishes Closing of Bookbuild Offering

EINDHOVEN, the Netherlands — October 28, 2024, 5:45pm CET — ONWARD Medical N.V. (Euronext: ONWD) (the “Company” or “ONWARD Medical”), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), announces today the closing of its previously announced private placement with institutional investors (the “Private Placement”).

24 Oct 24
ONWARD® Medical Publishes Prospectus for Listing of New Shares

EINDHOVEN, the Netherlands — October 24, 2024, 5:45pm CEST — ONWARD Medical N.V. (Euronext: ONWD) (the “Company” or “ONWARD Medical”), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), announces today that it has published a prospectus for the admission to listing of 10 million ordinary shares in the Company’s share capital, with a nominal value of EUR 0.12 each, issued through a private placement with institutional investors, for which pricing and allocation has occurred prior to trading on October 24, 2024 (the “Private Placement”).

24 Oct 24
ONWARD® Medical Successfully Raises EUR 50 Million in an Upsized Capital Increase with Cornerstone Investment from Ottobock SE & Co. KGaA

EINDHOVEN, the Netherlands — 7:30am October 24, 2024 — ONWARD Medical N.V. (the “Company”) (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces that it successfully raised an amount of EUR 50 million in gross proceeds by way of an upsized bookbuild offering through a private placement with institutional investors of 10 million new ordinary shares (the “Private Placement” and such shares the “New Shares”) via the Joint Bookrunners (as defined below). The New Shares were offered at an issue price of EUR 5.00 per share (the “Issue Price”).
 

Financial Calendar

More events are coming soon.

Recent Filings

ESG Information